Calithera Biosciences, Inc.
CALADrugs in Pipeline
8
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Fulvestrant
Breast Neoplasms
CB-839
Advanced Renal Cell Carcinoma
Paclitaxel
Triple Negative Breast Cancer
Telaglenestat (CB-839)
Solid Tumors
Sapanisertib
Breast Cancer
everolimus
Clear Cell Renal Cell Carcinoma
TAK-228
Renal Cell Carcinoma
Glutaminase Inhibitor CB-839
Colorectal Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Fulvestrant | Phase 2 | Breast Neoplasms | - | - |
CB-839 | Phase 2 | Advanced Renal Cell Carcinoma | - | - |
Paclitaxel | Phase 2 | Triple Negative Breast Cancer | - | - |
Telaglenestat (CB-839) | Phase 2 | Solid Tumors | - | - |
Sapanisertib | Phase 2 | Breast Cancer | - | - |
everolimus | Phase 2 | Clear Cell Renal Cell Carcinoma | - | - |
TAK-228 | Phase 2 | Renal Cell Carcinoma | - | - |
Glutaminase Inhibitor CB-839 | Phase 2 | Colorectal Cancer | - | - |
Frequently asked questions
What is in Calithera Biosciences, Inc.'s drug pipeline?→
CatalystAlert tracks 8 drug candidates in Calithera Biosciences, Inc.'s (CALA) pipeline across Phase 2. Its lead program is Fulvestrant (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Calithera Biosciences, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Calithera Biosciences, Inc. (CALA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CALA biotech catalysts?→
Add CALA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Calithera Biosciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.